GlassScriptPhysician profile
Ronald O Bailey
NPI 1104808914
$6,361.80
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,419 · 2020: $2,180 · 2021: $1,726 · 2023: $37.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,014.88 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $939.22 | 2020-2021 | |
| Genentech USA, INC. | $567.30 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $546.28 | 2019 | |
| Allergan, INC. | $529.08 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $527.03 | 2019-2021 | |
| Abbvie INC. | $391.92 | 2019-2021 | |
| Amgen INC. | $274.80 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $264.65 | 2019-2021 | |
| Genzyme Corporation | $164.96 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $147.35 | 2021 | |
| Tanabe Pharma America, INC. | $133.97 | 2019-2021 | |
| Livanova USA, INC. | $115.21 | 2020 | |
| Lilly USA, LLC | $111.27 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $71.36 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $68.96 | 2019 | |
| Boston Scientific Corporation | $52.32 | 2021-2023 | Superion Indirect Decompression System |
| Scilex Pharmaceuticals INC. | $48.67 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.38 | 2020-2021 | |
| Horizon Therapeutics Plc | $46.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $43.03 | 2019 | |
| Emd Serono, INC. | $40.98 | 2020 | |
| Avanir Pharmaceuticals, INC. | $37.60 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.68 | 2020 | |
| Lundbeck LLC | $22.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.51 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $21.23 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.72 | 2019 | |
| Merz North America, INC. | $17.75 | 2019 | |
| Mdd US Operations, LLC | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.